Amedisys, Inc. (NASDAQ:AMED) Position Lessened by Russell Investments Group Ltd.

Russell Investments Group Ltd. reduced its stake in shares of Amedisys, Inc. (NASDAQ:AMED) by 23.8% in the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 959 shares of the health services provider’s stock after selling 300 shares during the quarter. Russell Investments Group Ltd.’s holdings in Amedisys were worth $87,000 at the end of the most recent quarter.

Several other large investors have also recently added to or reduced their stakes in the stock. Trexquant Investment LP raised its stake in Amedisys by 1,317.8% during the 4th quarter. Trexquant Investment LP now owns 87,719 shares of the health services provider’s stock valued at $7,964,000 after acquiring an additional 81,532 shares in the last quarter. ABC Arbitrage SA acquired a new stake in Amedisys in the fourth quarter worth about $2,522,000. Oddo BHF Asset Management Sas acquired a new stake in Amedisys in the third quarter worth about $7,238,000. Empowered Funds LLC acquired a new position in Amedisys during the 4th quarter valued at about $318,000. Finally, KLP Kapitalforvaltning AS bought a new stake in shares of Amedisys during the 4th quarter worth about $590,000. 94.36% of the stock is owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

AMED has been the subject of several research reports. Royal Bank of Canada reaffirmed an “outperform” rating and set a $100.00 target price on shares of Amedisys in a research note on Wednesday, April 16th. Stephens restated an “equal weight” rating and set a $101.00 price objective on shares of Amedisys in a research report on Tuesday, March 4th. Four equities research analysts have rated the stock with a hold rating and two have given a buy rating to the company. According to MarketBeat, the stock presently has an average rating of “Hold” and a consensus target price of $100.75.

Amedisys Stock Up 0.2 %

Amedisys stock opened at $94.50 on Friday. Amedisys, Inc. has a twelve month low of $82.15 and a twelve month high of $98.95. The company has a debt-to-equity ratio of 0.05, a quick ratio of 1.19 and a current ratio of 1.19. The firm has a market cap of $3.10 billion, a PE ratio of 37.50, a P/E/G ratio of 1.78 and a beta of 0.89. The firm’s 50 day moving average price is $92.21 and its two-hundred day moving average price is $91.79.

Amedisys (NASDAQ:AMED) last posted its quarterly earnings results on Wednesday, April 23rd. The health services provider reported $1.25 earnings per share for the quarter, topping analysts’ consensus estimates of $1.13 by $0.12. The business had revenue of $594.78 million for the quarter, compared to the consensus estimate of $597.43 million. Amedisys had a net margin of 3.57% and a return on equity of 12.20%. On average, research analysts predict that Amedisys, Inc. will post 4.4 EPS for the current fiscal year.

Amedisys Company Profile

Amedisys, Inc, together with its subsidiaries, provides healthcare services in the United States. It operates through three segments: Home Health, Hospice, and High Acuity Care. The Home Health segment offers a range of services in the homes of individuals for the recovery of patients from surgery, chronic disability, or terminal illness, as well as prevents avoidable hospital readmissions through its skilled nurses; nursing services, rehabilitation therapists specialized in physical, speech, and occupational therapy; and social workers and aides for assisting its patients.